From: Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
Length of followup | Before propensity weighting | After propensity weighting | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RLX | ALN | P-value | RLX | ALN | P-value | |||||||||
% | Lower 95% CI | Upper 95% CI | % | Lower 95% CI | Upper 95% CI | % | Lower 95% CI | Upper 95% CI | % | Lower 95% CI | Upper 95% CI | |||
Vertebral Fracture | ||||||||||||||
1-year | 0.19% | 0.13% | 0.25% | 0.30% | 0.27% | 0.35% | 0.002 | 0.34% | 0.31% | 0.38% | 0.30% | 0.27% | 0.34% | 0.334 |
3-years | 0.67% | 0.50% | 0.83% | 1.00% | 0.89% | 1.14% | 0.002 | 0.93% | 0.83% | 1.03% | 0.97% | 0.87% | 1.08% | 0.720 |
5-years | 0.92% | 0.59% | 1.26% | 1.70% | 1.40% | 2.03% | 0.002 | 1.48% | 1.25% | 1.71% | 1.69% | 1.43% | 1.94% | 0.451 |
6-years | 1.20% | 0.60% | 1.81% | 1.99% | 1.44% | 2.54% | 0.083 | 1.28% | 0.93% | 1.64% | 1.90% | 1.46% | 2.34% | 0.169 |
7-years | 1.38% | 0.49% | 2.28% | 3.10% | 2.08% | 4.19% | 0.024 | 2.14% | 1.46% | 2.82% | 3.11% | 2.29% | 3.94% | 0.231 |
8-years | 0.92% | 0.00% | 2.19% | 3.32% | 1.39% | 5.25% | 0.071 | 3.70% | 2.12% | 5.27% | 3.80% | 2.19% | 5.41% | 0.952 |
Nonvertebral Fracture | ||||||||||||||
1-year | 1.96% | 1.78% | 2.14% | 2.20% | 2.10% | 2.31% | 0.023 | 2.36% | 2.27% | 2.45% | 2.15% | 2.06% | 2.24% | 0.056 |
3-years | 6.48% | 5.99% | 6.97% | 6.80% | 6.48% | 7.12% | 0.281 | 7.31% | 7.04% | 7.58% | 6.70% | 6.40% | 6.93% | 0.034 |
5-years | 9.71% | 8.67% | 10.75% | 11.80% | 11.05% | 12.61% | 0.002 | 10.73% | 10.14% | 11.33% | 11.48% | 10.85% | 12.12% | 0.271 |
6-years | 12.36% | 10.53% | 14.19% | 13.18% | 11.85% | 14.52% | 0.479 | 13.99% | 12.89% | 15.10% | 12.99% | 11.90% | 14.07% | 0.395 |
7-years | 13.85% | 11.19% | 16.50% | 15.29% | 13.12% | 17.46% | 0.414 | 17.53% | 15.74% | 19.32% | 15.29% | 13.58% | 17.01% | 0.222 |
8-years | 15.67% | 10.83% | 20.50% | 18.73% | 14.53% | 22.93% | 0.356 | 12.97% | 10.16% | 15.78% | 18.82% | 15.53% | 22.12% | 0.071 |